What is Amador Bioscience?
Founded in 2018 and headquartered in Pleasanton, California, Amador Bioscience operates as a transnational clinical pharmacology CRO. The company provides a comprehensive suite of services, including quantitative clinical pharmacology, GLP/GCLP bioanalysis, and clinical research support. By bridging the gap between early-stage drug discovery and regulatory approval, Amador Bioscience serves as a vital link for leading biopharmaceutical firms navigating the complexities of global clinical trials. Its market position is defined by its ability to provide high-standard, data-driven insights that streamline the path to market for novel therapeutics.
How much funding has Amador Bioscience raised?
Amador Bioscience has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2021): $60M with participation from CMB International Capital, Co-win Ventures, MSA Capital, GL Ventures, and Sequoia Capital
Key Investors in Amador Bioscience
CMB International Capital
CMB International Capital is the overseas integrated financial flagship platform of China Merchants Bank, providing comprehensive corporate finance services including IPO sponsorship and structured financing.
MSA Capital
MSA Capital is an independent global private equity and venture capital firm that partners with innovative entrepreneurs to deliver strong financial returns and positive social impact.
GL Ventures
GL Ventures is a consulting and investment firm that collaborates with CEOs and board members to develop growth strategies and facilitate organizational transitions for emerging companies.
What's next for Amador Bioscience?
With the successful closure of this major enterprise-level funding, Amador Bioscience is poised to enter a new phase of operational maturity. The strategic roadmap likely includes the expansion of its laboratory footprint to accommodate higher volumes of bioanalytical testing and the recruitment of specialized talent to support its growing regulatory filing practice. As the biopharmaceutical industry continues to prioritize efficiency and precision in clinical development, Amador Bioscience is strategically positioned to capture additional market share. The company will likely focus on deepening its technological integration, ensuring that its quantitative pharmacology models remain at the cutting edge of industry standards, thereby facilitating faster and more reliable drug development cycles for its global client base.
See full Amador Bioscience company page
